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Abstract 
Frizzled-6 (FZD6) gene, located on chromosome 8 
(8q22.3-q23.1), encodes a seven-transmembrane-
spanning protein belonging to the frizzled family of 
receptors for the Wnt (Wingless/Int-1) ligands. 
FZD6 is classified as G-protein-coupling receptor 
with a prevalent role in the non-canonical Wnt 
signaling pathway, a series of steps that affect the 
way cells and tissues develop. Specifically, FZD6-
mediated Wnt signaling is important for cell division 
(proliferation), adhesion and cellular movement 
(migration). It is active in many tissues and is 
involved during embryonic development, immune 
cells maturation and hematopoietic regeneration.  
After the Wnt-ligands binding, FZD6 protein is 
triggered at the cell surface to send signals into the 
cell and to initiate the Wnt signaling pathway. The 
encoded protein contains a signal peptide, a cysteine-
rich domain (CRD) in the extracellular N-terminal 
region, and seven transmembrane domains, but 
unlike other family members, this protein does not 
contain a C-terminal PDZ binding-domain motif. 
This protein acts as a negative regulator of the 
canonical Wnt/beta-catenin signaling cascade, 
thereby inhibiting the processes that trigger 
oncogenic transformation and inhibition of 
apoptosis. Alternative splicing results in multiple 
transcript variants, some of which do not encode a 
protein with a predicted signal peptide. 
Keywords 
FZD6, frizzled family receptor; Wnt Signalling 
Pathway; Leukemia; self renewal stem cells 
Identity 
Other names: Hfz6 
HGNC (Hugo): FZD6 
Location: Long (q) arm of chromosome 8 at position 
22.3; 8q22.3 
Location (base pair) 
Plus strand, starts at 103,298,433 and ends at 
103,332,866 bp from pter (according to hg19-Dec) 
Figure 1. FZD6 gene chromosomal location. 
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Figure 2. Chromosomal localization of FZD6 determined by FISH.  Here the plasmid HF6-1 was used as a probe and the 




FZD6 is a protein coding gene that comprises 8 
exons extending for about 41 kb of genomic DNA. It 
is located on human chromosome 8q22.3, it has 7 
transcripts, 82 orthologues, 12 paralogues and is 
associated with 3 phenotypes. 
Transcription 






Figure 3.  WNT10B-FZD6 interacting complexes in MOLT4 cell line (model of human acute T lymphoblastic leukaemia) were 
targeted by in situ Proximity ligation assay (PLA) with specific PLA probes. Rolling Circle Products (RCPs) were revealed with 
Cγ3 detection probes [Beghini A. unpublished data]. 
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Figure 4. FZD6 structure. The CRD is shaded in green, the 10 cysteine (C) residues forming five disulfide bonds is highlighted. 
DVL protein is also illustrated with DIX, PDZ and DEP domains and the non-interaction with FZD6 carboxyl tail is reported with a 




The Frizzled (FZD) gene was initially isolated as a 
Drosophilla tissue polarity gene (Adler et al., 1990) 
and later was characterized the human FZD gene 
homologue (Zhao et al., 1995).  
The Frizzled proteins are the receptors for WNT 
glycoproteins. Most of FZD are coupled with the β-
catenin canonical signaling pathway, which leads to 
nuclear translocation of these effectors and 
activation of Wnt target genes. Others two non-
canonical signaling pathways β-catenin-independent 
(Wnt-Ca2+  and planar cell polarity) involves PKC 
and intracellular calcium stores or the Rho family of 
GTPase, to regulate intracellular calcium levels or 
actin cytoskeleton reorganization.  
The FZD6 gene encodes a 706 amino-acid protein 
with seven transmembrane domains (amino acids 
202-222, 234-254, 284-305, 325-345, 371-391, 417-
437, 474-494) with a highly conserved cystein-rich 
domain (cysteine-rich domain, CRD) in the N-
terminal extracellular region (amino acids 1-18), 
which is necessary to the binding with Wnt-ligands. 
Almost all FZD receptors share a C-terminal portion 
(amino acids 495-706), spanning the KTxxxW 
motif, that is a binding site for the cytoplasmatic 
protein containing the PDZ domain (like a 
Dishevelled protein). However, unlike many other 
Fz family members (Tokuhara et al., 1998), FZD6 
does not contain a C-terminal PDZ domain-binding 
motif.  
The molecular mass of FZD6 protein is 79 kDa and 
alternative splicing results in multiple transcript 
variants, some of which are not involved in the 
encoding of proteins (see transcription section). 
Expression 
In Tokuhara's study (Tokuhara et al., 1998), 4,4 kb 
FZD6 mRNA was detected in several adult human 
tissues, like heart, brain, placenta, lung, liver, 
pancreas, kidney, thymus, colon, testis, ovary and 
other. In the fetus is expressed in brain, lung, liver 
and kidney. Furthermore, it was detected in many 
cancer cell lines among which MOLT4 (human 
acute T lymphoblastic leukaemia), A549 (lung 
cancer), SW480 (colon cancer), G361 (melanoma) 
and HeLa (cervical cancer) (Figure 5).  
In Wagner's study (Wagner et al., 2004), the FZD6 
gene overexpression was determined in slow-
dividing fraction (SDF) of hematopoietic 
progenitor cells (HPCs) within the CD34+ 
/CD38- population. 
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Figure 5. FZD6 mRNA expression analysis. (A) Adult human tissue.  (B)  Human cancer cell lines. The arrow indicates the 
FZD6 mRNA 4,4 kb position (Tokuhara et al., 1998). 
 
Localisation 
FZD6 is a multi-pass membrane protein, with seven 
transmembrane domains which have cysteine-rich 
domains (CRD) in N-terminal extracellular region 
and carboxyl tail in intracellular region. Trough the 
CRD, FZD6 receptor binds Wnt ligands in 
extracellular microenvironment. 
Function 
Frizzled receptors mediate Wnt ligand signalling, 
which is crucially involved in regulating tissue 
development and differentiation, and is often 
deregulated in cancer.  
Fzd6 is generally associated with PCP (planar cell 
polarity) signaling in epithelial cells: for example, it 
was shown that controls macroscopic hair patterning 
in the mouse. Both epithelial cells and melanocytes 
are FZD6 expression sites (Guo et al., 2004).  
Data from Golan's study (Golan et al., 2004), suggest 
that human FZD6 activates the transforming growth 
factor-β-activated kinase-NEMO-like kinase ( NLK) 
pathway that blocks nuclear LEF1 (TCF/LEF, T cell 
factor/lymphoid enhancer factor) binding to target 
promoters, thus repressing the ability of CTNNB1 
(β-catenin) to activate transcription of Wnt target 
genes. The FZD6 protein blocks canonical Wnt 
pathway through cross-talks with repressors Wnt 
signaling downstream of the β-catenin destruction 
complex. Indeed, human FZD6 does not change the 
cellular levels of β-catenin, suggesting that the 
ectopically expressed FZD6 does not destabilize the 
β-catenin. In this respect, the FZD6 does not 
interfere with nuclear translocation of β-catenin or 
theirs TCF-binding, but the repressive activity is 
mediated by inhibition of TCF/LEF binding and 
TCF/β-catenin complexes formation to target DNA.  
Furthermore, Kilander's study (Kilander et al., 2014) 
identified FZD6 as a G-protein-coupled receptors 
(GPCR) and Disheveled (DVL1) protein as a master 
regulator of FZD6/G-protein coupling, which at high 
levels can also act as negative regulator of Wnt/FZD- 
induced G protein signaling. DIX domain of DVL is 
responsible for the negative regulation of FZD6-G-
protein precoupling.  
Frizzled-6 (Fzd6), regulates hematopoietic 
stem/progenitor cell (HSPC) expansion and survival 
in a hematopoietic cell-intrinsic manner.  
Abidin's research (Abidin et al., 2015) showed that 
FZD6-/- HSCs are able to localize in the bone marrow 
but it does not reconstitute a lethally irradiated host. 
The FZD6 deficiency impaires the expansion and 
survival of HSCs, resulting in activation of caspase-
3 (CASP3) and weak HSCs engraftment after bone 
marrow transplant in C57BL/6 mice.  
The non-canonical Wnt receptor FZD6, is also 
necessary for HSC expansion during emergency 
hematopoiesis.  
FZD6 is involved in the neural tube closure and plays 
a role in the regulation of the establishment of planar 
cell polarity (PCP), together with FZD3, particularly 
in the orientation of asymmetric bundles of 
stereocilia in a group of auditory and vestibular 
sensory cells located in the inner ear (De Marco et 
al., 2011). 
Homology 
The FZD6 gene is conserved in chimpanzee, Rhesus 
monkey, dog, cow, mouse, rat, chicken, zebrafish, 
and frog. 
Mutations 
De novo frameshift mutation c.1843_1844insA 
(p.Cys615X)= it introduces a premature stop codon 
and encodes for a truncated protein that lacks the last 
51 amino-acids in carboxyl-terminal tail.  
De novo frameshift mutation c.1843_1844insA 
(p.Cys615X)= it introduces a premature stop codon 
and encodes Missense changes c.1214G>A 
(p.Arg405Gln) = the mutation changes a positively 
charged residue into a hydrophilic uncharged 
residue. Its prediction suggests that it is probably a 
pathogenic protein.  
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Figure 6. FZD6 variants. Schematic model of FZD6 gene  (A) and protein  (B) with the locations of the rare variants involved in 
Neural tube defects (NTDs). In red are framed FZD6 mutations  which are absent in controls of NTDs and which are predicted to 
have a functional effect. CRD= cysteine-rich domain (De Marco et al., 2011). 
 
Missense changes c.1531C>T (p.Arg511Cys)= this 
variant introduces a cysteine in a conserved region 
and may result in abnormal conformational changes 
of the protein. Missense changes c.1532G>A 
(p.Arg511His)= the variant represents an exchange 
of two basic amino-acids in a conserved region.  
Single nucleotide substitution (c.20C>T) = affecting 
the 3' UTR of the FZD6 gene. This substitution 
changed the target site for miR628, whichcould 
cause changes in FZD6 gene regulation.  
Homozygous nonsense mutation c.1750G>T (p. 
Glu584X) = mutation involved in autosomal-
recessive nail dysplasia. The G>T transition in exon 
6 of FZD6 changes the codon GAA (encoding 
glutamic acid) to TAA (stop codon). This induces 
the truncated protein formation, lacking the C-
terminus. To determine his functional effect, Naz' s 
group (Naz et al., 2012) carried out 
immunofluorescence analysis, which revealed the 
presence of a mutant FZD6 protein in the cell 
membrane. The KTxxxW motif is also present in 
FZD6 mutant form, so could be that Wnt ligands 
may still be able to bind to truncated protein, leading 
to recruitment of DVL protein but no of other 
cytoplasmic mediators such as G proteins (Figure 7).  
Missense mutation c.1531C>T (p.Arg511Cys) = 
mutation involved in autosomal-recessive nail 
dysplasia. The changed arginine residue is conserved 
in several species, supporting the potential 
functional importance of this variant. It was 
observed that FZD6 changed protein with this 
mutation is confined to intracellular vesicles 
(lysosomes), where is probably degraded (Figure 7. 
Fröjmark et al., 2011). Then was also seen that 
FZD6-Arg511Cys mutation is incapable of G-
protein precoupling, even though it still binds DVL  
(Kilander et al., 2014)  
Missense mutation c.1266G>A (p.Gly422Asp) = 
mutation involved in autosomal-recessive nail 
dysplasia. The changed glycine residue is conserved 
in several species, supporting the potential 
functional importance of this variant. Variant is 
located in the sixth transmembrane domain of the 
mutant FZD6 protein, suggesting that FZD6 mutant 
can affect binding of Wnt ligand. It is highly likely 
that also this mutant FD6 is confined and degraded 




The Wu's study (Wu et al., 2009) showed that, during 
the leukemogenesis in Eμ-TCL1 mouse model of 
chronic lymphocytic leukemia, the expression of 
FZD6 is dramatically up-regulated in the 
transformed CD5+ B cells of this animal model. 
FZD6 gene ablation strongly decreases the 
development and tumor growth of chronic 
lymphocytic leukemia. The dramatic up-regulation 
of FZD6 was recorded both during a preleukemic 
clonal expansion and during the transformation to a 
monoclonal leukemia. Mouse FZD6 differs from its 
human homolog, which is able to inhibit the 
canonical signaling pathway. Indeed, in Eμ-TCL1 
mouse model, it was highlighted the over-expression 
of intracellular β-catenin levels in FZD6+/+ leukemic 
B cells, while in FZD6-/- leukemic cells the β-catenin 
levels were physiological. This evidence suggests 
that mouse FZD6 receptor up-regulation activates 
the Wnt canonical pathway. 
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Figure 7. Representation of the human FZD6 protein domains. Positions of the FZD6 mutations involved in autosomal-
recessive nail dysplasia are shown with an arrow. 
 
Breast Cancer 
Corda's study (Corda et al., 2017) describes that, in 
according to Sanger Institute Cosmic repository, 
about 20% of breast sample showed FZD6 copy 
number gains or gene overexpression. Particularly, 
FZD6 copy number increase was more frequent in 
triple-negative (TNBC; 87.1%) than in non-triple-
negative (61.7%) or ER-positive (72%) breast cancer 
cases. Expression of Wnt non-canonical FZD6 
ligands, as WNT11 and WNT5B, was also increased 
in TNBC samples, suggesting that a non-canonical 
pathway may be involved downstream of FZD6 
receptor. Furthermore, they investigated FZD6 role 
in motility, proliferation and invasion of breast 
cancer cell lines. The depletion or inhibition with 
short-hairpin RNAs (shRNAs) or small interfering 
RNAs (siRNAs) respectively caused a significant 
reduction of these functions. Next they used an 
organoid 3D cultures to determine the degree of 
transformation of breast cancer cells: the 
overexpression of FZD6 induces disorganized 3D 
growth, supporting a more aggressive phenotype and 
suggesting the hypothesis that the receptor is a 
mammary protooncogene. Finally, they carried out 
immunohistochemical analysis with an FZD6 
antibody in a retrospective Italian cohort with node-
negative early breast cancer. Kaplan-Meier analysis 
indicated that FZD6 expression was associated with 
reduced distant relapse-free survival (DFRS) in the 
TNBC patient subtype. In other subgroup, there was 
not significant association.  
However, the Wnt10B/FZD6 interaction in adherent 
and tumorsphere culture of MCF-7 breast cancer cell 
line has been investigated, using proximity ligation 
assay (PLA) (Lazzaroni et al., 2016), results did not 
detect any interacting complexes in MCF7. 
Colorectal cancer (CRC) 
The CRC is one of the most common neoplasms 
worldwide and Wnt signalling is among the 
biochemical pathways involved in pathogenesis, 
because it drives a stem molecular program in 
several intestinal cells. FZD6 is highly expressed in 
CRC tissue and cell lines, such as FZD3 and FZD7, 
but its role in the disease is still unclear (Vincan et 
al., 2008). 
Prostate tumors 
In Wissmann's study (Wissmann et al., 2003) a 
FZD6 high gene expression was detected by chip 
hybridization in primary prostate cancer samples. At 
the RNA level in microdissected prostate tumor 
samples, FZD6 was found up-regulated.  
This evidence was confirmed in another study 
(Saramäki et al., 2006): the analysis was performed 
by cDNA microarray expression on prostate cancer 
cell lines (LNCaP, DU145, PC-3, 22Rv1 and LAPC-
4) and xenografts. The FZD6 gene showed 
significant association between increased copy 
number and overexpression. 
Neuroblastoma 
According to Cantilena's work (Cantilena et al., 
2011), the presence of FZD6 anticipates poor 
survival in neuroblastoma patients and remarks 
HIF1/2 α-positive cells in cancer hypoxic areas.  
Neuroblastoma is an early cancer developing neural 
crest and Wnt signalling plays an important role in 
formation and migration of these multipotent cells. 
The study initially found out that only FZD6, among 
FZD family receptors, was statistically significantly 
associated with poor survival of neuroblastoma 
patients.  
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FZD6 positive neuroblastoma cells are rare highly 
tumorigenic stem-like cells, which form resistant-
doxorubicin neurospheres. FZD6 activity is crucial 
in neurospheres formation, because this 
phenomenon is very reduced in cell transfected with 
FD6-siRNA, as well as the expression of non-
canonical Wnt-target genes CD44 and TH. FZD6 
expression is also associated with aggressive growth 
and capacity to metastasize in vivo, as highlighted by 
high expression of NOTCH1, ki67 (proliferation 
marker) and mesenchymal stem cell marker 
TWIST1 in FZD6+ cells. 
Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) originates mostly 
in cirrhotic livers and the dysregulation of 
pleiotropic growth factors, such as Wnt signaling 
pathway, plays an essential role in 
hepatocarcinogenesis. Wnt is involved in 
proliferation and antiapoptotic behavior of cancer 
cells. In Bengochea's research (Bengochea et al., 
2008), was detected the FZD6/FZD3/FZD7 
overexpression in HCC cells in association with the 
concomitantly upregulation of three Wnt agonists 
(WNT3, WNT4 and WNT5A) and downregulation 
of two Wnt antagonists (SFRP1 and SFRP5). 
Furthermore, the study showed that at least one over 
the three Wnt/FZD pathways (canonical β-catenin, 
or noncanonical PKC and JNK) during 
carcinogenesis is activated in most cases of HCC 
samples. 
Squamous cell carcinoma 
Squamous cell carcinoma (SCC) typically has an 
aggressive behavior and is made up of epithelial 
cells, which are hyperplastic and invasive. 
Upregulation of FZD6 RNA level in malignant 
samples was detected by global gene expression 
profiling performed on SCC cells and on normal skin 
cells from patients. The FZD6 expression was not 
increased in psoriasis samples and it was absent in 
benign hyperplasia. According to this data, it is 
possible that FZD6 is involved in noncanonical Wnt-
signalling in SCC (Haider et al., 2006). 
Neural tube defects (NTDs) 
Neural tube defects (NTDs) are a set of pathological 
conditions of the central nervous system (CNS) and 
are one of the most common birth defects, affecting 
1 of 1000 live births. De Marco's study (De Marco et 
al., 2011) identified five rare FZD6 variants 
predicted to have a functional effect by 
computational analysis, suggesting an involvement 
of FZD6 mutations in NTDs pathogenesis. One of 
the main cellular event occurring during early 
development of CNS is convergent extension, that is 
mediated by planar cell polarity (PCP) pathway and 
its Frizzled receptors family. Expression studies in 
humans showed that FZD6 is highly expressed in 
both embryonic and adult tissues, including brain 
and CNS (Tokuhara et al., 1998).  
The five rare FZD6 variants are: one de novo 
frameshift mutation that introduces a premature stop 
codon (Cys615X), three missense variants 
(Arg405Gln, Arg511Cys and Arg511His) and a 
single nucleotide substitution (20C>T), affecting 
3'UTR (see mutations section). Most of the 
mutations are located in the FZD6 protein 
intracellular domains and they are absent in all the 
investigated controls and suggesting a high 
involvement of FZD6 gene in the pathogenesis of a 
minority of NTDs (De Marco et al., 2011).  
Based on this evidence, Shi's study (Shi et al., 2014) 
analyzed FZD6 single nucleotide polymorphisms 
(rs827528, rs3808553 and rs12549394) in a group of 
135 NTD patients and 135 controls in the Han 
population of northern China. The children with 
genotype rs3808553 (G>T, localized at residue 345 
of exon 4) had an increased risk of NTDs, but the 
other two genotypes did not shown correlation with 
NTDs. The s3808553 polymorphism in the fourth 
transmembrane domain of FZD6 protein could be a 
potential genetic risk factor for NTDs in this Chinese 
population. 
Autosomal recessive nail dysplasia 
Isolated nail dysplasia is a rare disorder and the 
FZD6 gene was identified in families with 
autosomal-recessive nail dysplasia. Naz et al. 
(2011), investigated two Pakistani families with this 
disorder and performed a genetic analysis on the 
chromosome 8q22.3, where FZD6 gene is located. 
Sequence analysis identified a homozygous 
nonsense mutation (c.1750G>T) in exon 6 
of FZD6 in all affected individuals from both family. 
This transition changes the codon GAA (encoding 
glutamic acid) to TAA (stop coding), producing a 
premature block of translation and a truncated 
protein lacking the C-terminus. The glutamic acid 
residue is highly conserved among species, thus 
indicating its functional importance. In vitro assays 
have shown that the FZD6 mutant protein abolishes 
FZD6 repressive activity on canonical Wnt/β-
catenin pathway. It is already known that the loss of 
inhibition of the canonical signaling, due to FZD6 
mutant, leads to excessive nail growth in humans.  
The previous study also confirmed another 
homozygous missense mutation (c.1531C>T 
[p.Arg511Cys]) and a nonsense mutation 
(c.1750G>T [p.Glu584X]), identified by Fröjmark' s 
research (Fröjmark et al. 2011) by two Pakistani 
families similarly affected by autosomal-recessive 
isolated nail dysplasia. Both FZD6 mutations result 
in alterations of the intracellular tail, which could 
cause an increased protein degradation, that is an 
improper receptor integration into the cell membrane 
or a reduced capability to DVL recruitment.  
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The Raza's study (Raza et al., 2012) carried out on 
six Pakistani individuals, showed a FZD6 missense 
mutation c.1266G>A (p.Gly422Asp). Furthermore, 
a panel of 300 unaffected control individuals was 
screened, to exclude the possibility that the missense 
mutation does not represent a nonpathogenic 
polymorphism and the mutation c.1266G>A was not 
identified (see mutations section). 
Depression 
FZD6 mRNA level were significantly increased in 
the hippocampus, following chronic 
electroconvulsive seizure (Chr-ECS), one of the 
most effective treatments for depressed patients. 
Indeed, Chr-ECS increases the level of transcription 
factor CREB1, which is able to regulate the gene 
expression of FZD6, whereas FZD6 mRNA level 
was decreased in a depressed rodent model after 
exposure to chronic unpredictable stress (CUS). 
ShRNA strategy experiments were performed to 
achieve FZD6 mRNA knockdown in the adult rat 
hippocampus and the FZD6 mRNA levels reduction 
was confirmed. In this animal model, the knockdown 
of FZD6 causes anhedonic behavior, a core symptom 
of depression. Furthermore, the anxiety in the 
novelty suppressed feeding test was increased, a 
typical behavior of CUS exposure. This evidence 
suggests that FZD6 could represent a novel target for 
development of novel antidepressants (Voleti et al., 
2012). 
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